(secondQuint)Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults.

 This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor.

 Verdinexor or placebo will be given on days 1 and 3 to healthy adult subjects.

 Cohorts of 8 subjects each (6 active, 2 placebo) will be sequentially administered verdinexor or placebo (one dose on Day 1 and one dose on Day 3) using a dose-escalation scheme.

 A conservative, sequential, dose-escalation strategy employing decreasing escalation increments will be used.

.

 Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults@highlight

This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor.

 Verdinexor or placebo will be given on days 1 and 3 to healthy adult subjects.

